查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600591

細胞株開拓市場：按類型、來源、產品、應用分類 - 2025-2030 年全球預測

Cell Line Development Market by Type (Continuous Cell Lines, Hybridomas, Primary Cell Lines), Source (Amphibian, Insect, Mammalian), Product, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

細胞株開拓市場2023年估值為56.9億美元，預計2024年將達到64.9億美元，複合年成長率為14.34%，預計到2030年將達到145.4億美元。

細胞株開拓在生物製藥研究和生產中發揮著至關重要的作用，創建了藥物開發、基因研究和治療應用所必需的細胞模型。這個過程涵蓋初始細胞採購、基因操作和培養，對於單株抗體、疫苗和蛋白質的生產至關重要。該領域的需求在於其對個人化醫療、再生療法和生技藥品生產效率的核心作用。主要應用涵蓋生物製藥、生物技術和醫療保健領域，最終用戶包括製藥公司、醫療保健研究機構和學術機構。市場成長受到生技藥品需求增加、細胞培養技術進步以及研發資金增加的顯著影響。新的研發機會將重點放在開發用於癌症研究、精準醫學和增強 CRISPR 技術的強大細胞株。鼓勵公司投資自動化和一次性技術，以利用生產效率和擴充性。儘管具有成長潛力，但該領域面臨一些限制，例如初始設置成本高、法律規範嚴格以及維持細胞株穩定性和重現性方面的挑戰。 3D 細胞培養、連續處理和用於細胞株選擇的人工智慧等創新有望提高製程效率和產品質量，為研究和開發提供成熟的途徑。在生物加工的進步以及旨在簡化管道的戰略夥伴關係和聯盟的增加的推動下，市場充滿活力和競爭。隨著情勢的發展，企業必須成功平衡成本控制和技術創新，以保持競爭優勢。新興趨勢凸顯了整合尖端基因組技術和生物資訊學工具以最佳化細胞株特性和增強治療效果的必要性，在細胞株開拓領域開闢新的適應症和市場為探索領導地位提供了前沿。

主要市場統計
基準年[2023] 56.9億美元
預測年份 [2024] 64.9億美元
預測年份 [2030] 145.4億美元
複合年成長率（%） 14.34%

市場動態：快速發展的細胞株開拓市場的關鍵市場洞察

供需的動態交互作用正在改變細胞株開拓市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於應用範圍擴大，對單株抗體的需求增加
    • 創新技術以及研究和政府機構的更多參與
    • 疫苗產量增加
  • 市場限制因素
    • 產品及應用認知度低，高成本
  • 市場機會
    • 感染性疾病的風險增加
    • 低收入國家的可能性
  • 市場挑戰
    • 開發可靠且穩定的細胞株

波特的五力：駕馭細胞株開拓市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解細胞株開拓市場的外部影響

外部宏觀環境因素在塑造細胞株開拓市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解細胞株開拓市場的競爭狀況

細胞株開拓市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣細胞株開拓市場廠商績效評估

FPNV定位矩陣是評估細胞株開拓市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於應用範圍不斷擴大，對單株抗體的需求不斷增加
      • 創新技術以及研究和政府機構的更多參與
      • 疫苗產量增加
    • 抑制因素
      • 產品及應用認知度低，高成本
    • 機會
      • 感染性疾病的風險增加
      • 低收入國家的潛力
    • 任務
      • 開發可靠且穩定的細胞株
  • 市場區隔分析
    • 類型：連續細胞株係由於其穩健性和易於工作而擴大在研究活動中被採用。
    • 來源：擴大使用哺乳動物細胞株來生產治療分子
    • 產品：將先進技術整合到細胞株開拓設備中
    • 應用：生物生產對可擴展且可靠的細胞株開拓策略的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化
    • 技術進步
      • 胺基甲基葉酸放大技術
      • 麩醯胺酸合成酶技術
      • 基於病毒的技術

第6章細胞株開拓市場：依類型

  • 連續性細胞株
  • 融合瘤
  • 初代細胞系
  • 重組細胞株

第 7 章細胞株開拓市場：依來源分類

  • 兩棲類
  • 昆蟲
  • 哺乳動物的

第 8 章細胞株開拓市場：依產品

  • 裝置
    • 自動化系統
    • 反應器
    • 生物安全櫃
    • 細胞計數器和活力測量系統
    • 離心機
    • 過濾系統
    • 培養箱
    • 顯微鏡
    • 倉儲設備
  • 介質和試劑
    • 媒體
      • 最少所需介質
      • 減少血清培養基
      • 無血清培養基
    • 試劑
      • 緩衝液和化學品
      • 細胞分離試劑
      • 凍存試劑
      • 補充品和生長因子
    • 血清
      • 牛血清
      • 牛

第9章細胞株開拓市場：依應用分類

  • 生物生產
    • 診斷
    • 重組蛋白療法
    • 疫苗生產
  • 藥物發現
    • 疾病模型
    • 藥物篩檢與開發
    • 目標檢驗
  • 調查
  • 組織工程與再生醫學
  • 毒性試驗

第10章 北美和南美細胞株開拓市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區細胞株開拓市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的細胞株開拓市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • FairJourney Biologics 選擇 Sphere Fluidics 的 Cyto-Mine 系統來推進細胞株開拓工作流程
    • 布魯克公司和 Phenomex 宣布布魯克以全現金交易收購 Phenomex 的最終協議
    • KBI Biopharma 推出 KBI PURE 平台，這是一種用於生物製藥製造的微生物表現解決方案

公司名單

  • Boehringer Ingelheim International GmbH
  • Aragen Life Sciences Ltd.
  • Eurofins Scientific
  • Rentschler Biopharma SE
  • PromoCell GmbH
  • KBI Biopharma by JSR Life Sciences, LLC
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Thermo Fisher Scientific Inc.
  • Vista Biologicals Corporation
  • Merck KGaA
  • WuXi Biologics Co., Ltd.
  • Novartis AG
  • EuBiologics Co.,Ltd.
  • Lonza Group Ltd.
  • Syngene International Ltd.
  • Danaher Corporation
  • GenScript Biotech Corporation
  • GE HealthCare Technologies Inc.
  • Samsung Biologics Co., Ltd.
  • Catalent, Inc.
  • AGC Biologics
  • Corning Incorporated
  • Cyagen
  • Sartorius AG
  • Advanced Instruments, LLC
Product Code: MRR-43078BB92CCA

The Cell Line Development Market was valued at USD 5.69 billion in 2023, expected to reach USD 6.49 billion in 2024, and is projected to grow at a CAGR of 14.34%, to USD 14.54 billion by 2030.

Cell line development plays a pivotal role in biopharmaceutical research and production, creating essential cellular models for drug development, genetic research, and therapeutic applications. The process spans from initial cell sourcing to genetic manipulation and culturing, critical for producing monoclonal antibodies, vaccines, and proteins. This field's necessity lies in its centrality to personalized medicine, regenerative therapies, and biologics production efficiency. Key applications extend across biopharmaceutical, biotechnology, and healthcare sectors, with end-users including pharmaceutical companies, healthcare research organizations, and academic institutions. Market growth is significantly influenced by rising demand for biologics, advancements in cell culture technology, and increased funding for R&D. Emerging opportunities are noted in the development of robust cell lines for cancer research, precision medicine, and CRISPR technology enhancements. Companies are recommended to invest in automation and single-use technologies to capitalize on production efficiency and scalability. Despite its growth potential, the sector faces limitations such as high initial setup costs, stringent regulatory frameworks, and challenges in maintaining cell line stability and reproducibility. Innovations in 3D cell cultures, continuous processing, and artificial intelligence for cell line selection present ripe avenues for research and development, promising to enhance process efficiency and product quality. The market is dynamically competitive, driven by advancements in bioprocessing and increasing strategic partnerships and collaborations aimed at streamlining the cell line development pipeline. As the landscape evolves, companies must navigate the balance between cost management and technological innovation to maintain competitive advantage. Emerging trends highlight the necessity of integrating cutting-edge genomic techniques and bioinformatics tools to optimize cell line characteristics and enhance therapeutic outputs, offering a frontier for exploring new efficacies and market leadership in the cell line development domain.

KEY MARKET STATISTICS
Base Year [2023] USD 5.69 billion
Estimated Year [2024] USD 6.49 billion
Forecast Year [2030] USD 14.54 billion
CAGR (%) 14.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell Line Development Market

The Cell Line Development Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase Demand for Monoclonal Antibodies Owing to Increase Application
    • Innovative Technologies Coupled with Increased Participation of Research Institutes and Government Agency
    • Growing Rise in Vaccine Production
  • Market Restraints
    • Limited Awareness and High Cost Associated with The Product and Applications
  • Market Opportunities
    • Increasing Risk of Communicable Epidemics Diseases
    • Potential in Low-income Countries
  • Market Challenges
    • Developing Authentic and Stable Cell Lines

Porter's Five Forces: A Strategic Tool for Navigating the Cell Line Development Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell Line Development Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell Line Development Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell Line Development Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell Line Development Market

A detailed market share analysis in the Cell Line Development Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell Line Development Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell Line Development Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cell Line Development Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Aragen Life Sciences Ltd., Eurofins Scientific, Rentschler Biopharma SE, PromoCell GmbH, KBI Biopharma by JSR Life Sciences, LLC, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Thermo Fisher Scientific Inc., Vista Biologicals Corporation, Merck KGaA, WuXi Biologics Co., Ltd., Novartis AG, EuBiologics Co.,Ltd., Lonza Group Ltd., Syngene International Ltd., Danaher Corporation, GenScript Biotech Corporation, GE HealthCare Technologies Inc., Samsung Biologics Co., Ltd., Catalent, Inc., AGC Biologics, Corning Incorporated, Cyagen, Sartorius AG, and Advanced Instruments, LLC.

Market Segmentation & Coverage

This research report categorizes the Cell Line Development Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Continuous Cell Lines, Hybridomas, Primary Cell Lines, and Recombinant Cell Lines.
  • Based on Source, market is studied across Amphibian, Insect, and Mammalian.
  • Based on Product, market is studied across Equipment and Media and Reagents. The Equipment is further studied across Automated Systems, Bioreactors, Biosafety Cabinets, Cell Counters and Viability Systems, Centrifuges, Filtration Systems, Incubators, Microscopes, and Storage Equipment. The Media and Reagents is further studied across Media, Reagents, and Serum. The Media is further studied across Minimum Essential Media, Reduced Serum Media, and Serum-free Media. The Reagents is further studied across Buffers and Chemicals, Cell Dissociation Reagents, Cryopreservative Reagents, and Supplements and Growth Factors. The Serum is further studied across Adult Bovine Serum and Fetal Bovine Serum.
  • Based on Application, market is studied across Bioproduction, Drug Discovery, Research, Tissue Engineering & Regenerative Medicine, and Toxicity Testing. The Bioproduction is further studied across Diagnostics, Recombinant Protein Therapeutics, and Vaccine Production. The Drug Discovery is further studied across Disease Modeling, Drug Screening and Development, and Target Validation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase Demand for Monoclonal Antibodies Owing to Increase Application
      • 5.1.1.2. Innovative Technologies Coupled with Increased Participation of Research Institutes and Government Agency
      • 5.1.1.3. Growing Rise in Vaccine Production
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Awareness and High Cost Associated with The Product and Applications
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Risk of Communicable Epidemics Diseases
      • 5.1.3.2. Potential in Low-income Countries
    • 5.1.4. Challenges
      • 5.1.4.1. Developing Authentic and Stable Cell Lines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing adoption of continuous cell lines in research activities due to their robustness and ease of work
    • 5.2.2. Source: Rising utilization of mammalian sources of cell lines for the production of therapeutic molecules
    • 5.2.3. Product: Integration of advanced technologies in equipment for cell line development
    • 5.2.4. Application: Need for scalable and reliable cell line development strategies for bioproduction
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Technology Advancement
      • 5.5.1.1. Methotrexate Amplification Technology
      • 5.5.1.2. Glutamine Synthatase Technology
      • 5.5.1.3. Viral-Based Technology

6. Cell Line Development Market, by Type

  • 6.1. Introduction
  • 6.2. Continuous Cell Lines
  • 6.3. Hybridomas
  • 6.4. Primary Cell Lines
  • 6.5. Recombinant Cell Lines

7. Cell Line Development Market, by Source

  • 7.1. Introduction
  • 7.2. Amphibian
  • 7.3. Insect
  • 7.4. Mammalian

8. Cell Line Development Market, by Product

  • 8.1. Introduction
  • 8.2. Equipment
    • 8.2.1. Automated Systems
    • 8.2.2. Bioreactors
    • 8.2.3. Biosafety Cabinets
    • 8.2.4. Cell Counters and Viability Systems
    • 8.2.5. Centrifuges
    • 8.2.6. Filtration Systems
    • 8.2.7. Incubators
    • 8.2.8. Microscopes
    • 8.2.9. Storage Equipment
  • 8.3. Media and Reagents
    • 8.3.1. Media
      • 8.3.1.1. Minimum Essential Media
      • 8.3.1.2. Reduced Serum Media
      • 8.3.1.3. Serum-free Media
    • 8.3.2. Reagents
      • 8.3.2.1. Buffers and Chemicals
      • 8.3.2.2. Cell Dissociation Reagents
      • 8.3.2.3. Cryopreservative Reagents
      • 8.3.2.4. Supplements and Growth Factors
    • 8.3.3. Serum
      • 8.3.3.1. Adult Bovine Serum
      • 8.3.3.2. Fetal Bovine Serum

9. Cell Line Development Market, by Application

  • 9.1. Introduction
  • 9.2. Bioproduction
    • 9.2.1. Diagnostics
    • 9.2.2. Recombinant Protein Therapeutics
    • 9.2.3. Vaccine Production
  • 9.3. Drug Discovery
    • 9.3.1. Disease Modeling
    • 9.3.2. Drug Screening and Development
    • 9.3.3. Target Validation
  • 9.4. Research
  • 9.5. Tissue Engineering & Regenerative Medicine
  • 9.6. Toxicity Testing

10. Americas Cell Line Development Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell Line Development Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell Line Development Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sphere Fluidics' Cyto-Mine System Selected by FairJourney Biologics To Advance Cell Line Development Workflows
    • 13.3.2. Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction
    • 13.3.3. KBI Biopharma Unveils KBI PUREplatform, a Microbial Expression Offering for Biopharmaceutical Manufacturing

Companies Mentioned

  • 1. Boehringer Ingelheim International GmbH
  • 2. Aragen Life Sciences Ltd.
  • 3. Eurofins Scientific
  • 4. Rentschler Biopharma SE
  • 5. PromoCell GmbH
  • 6. KBI Biopharma by JSR Life Sciences, LLC
  • 7. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 8. Thermo Fisher Scientific Inc.
  • 9. Vista Biologicals Corporation
  • 10. Merck KGaA
  • 11. WuXi Biologics Co., Ltd.
  • 12. Novartis AG
  • 13. EuBiologics Co.,Ltd.
  • 14. Lonza Group Ltd.
  • 15. Syngene International Ltd.
  • 16. Danaher Corporation
  • 17. GenScript Biotech Corporation
  • 18. GE HealthCare Technologies Inc.
  • 19. Samsung Biologics Co., Ltd.
  • 20. Catalent, Inc.
  • 21. AGC Biologics
  • 22. Corning Incorporated
  • 23. Cyagen
  • 24. Sartorius AG
  • 25. Advanced Instruments, LLC

LIST OF FIGURES

  • FIGURE 1. CELL LINE DEVELOPMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CELL LINE DEVELOPMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL LINE DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL LINE DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL LINE DEVELOPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL LINE DEVELOPMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CONTINUOUS CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY HYBRIDOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRIMARY CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RECOMBINANT CELL LINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY AMPHIBIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY INSECT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOSAFETY CABINETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL COUNTERS AND VIABILITY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY INCUBATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MINIMUM ESSENTIAL MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REDUCED SERUM MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM-FREE MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BUFFERS AND CHEMICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CELL DISSOCIATION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY CRYOPRESERVATIVE REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SUPPLEMENTS AND GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY ADULT BOVINE SERUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY FETAL BOVINE SERUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEIN THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG SCREENING AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CELL LINE DEVELOPMENT MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES CELL LINE DEVELOPMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 187. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 198. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 199. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 209. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 210. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 211. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 220. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 221. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 222. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 232. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 233. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 242. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 243. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 244. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 253. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 254. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 255. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 264. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 265. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 266. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 267. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CELL LINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 287. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 288. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 289. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 290. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 291. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 292. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 293. DENMARK CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 298. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 299. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 300. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 301. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 302. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 304. EGYPT CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 309. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 310. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 311. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 312. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 313. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 315. FINLAND CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 320. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 321. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 322. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 323. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 324. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 325. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 326. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 331. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 332. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 333. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 334. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 335. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 336. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY BIOPRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 337. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 338. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 340. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 342. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA AND REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 343. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY MEDIA, 2018-2030 (USD MILLION)
  • TABLE 344. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 345. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY SERUM, 2018-2030 (USD MILLION)
  • TABLE 346. ISRAEL CELL LINE DEVELOPMENT MARKET SIZE, BY APPLICATION, 2018-2030 (U